Cinnarizine tablets 25mg, No. 56

• the period of convalescence after suffering ischemic and hemorrhagic stroke, traumatic brain injury;

• encephalopathy;

• labyrinth disorders (including for maintenance therapy for dizziness, tinnitus, nystagmus, nausea, vomiting of labyrinthine origin);

• migraine (prevention of attacks);

• Meniere's disease;

• seasickness and air sickness (prevention);

• violation of peripheral circulation (prevention and treatment) - obliterating endarteritis, thromboangiitis obliterans, Raynaud's disease, diabetic angiopathy, thrombophlebitis, trophic disorders, trophic and varicose ulcers, pregangrenous conditions, paresthesias, night cramps and coldness in the extremities.

Inside, after eating.

In case of cerebral circulation disorders - 25-50 mg 3 times a day;

In case of peripheral circulatory disorders - 50-75 mg 3 times a day;

For labyrinthine disorders - 25 mg 3 times a day;

For sea ??and air sickness, before the upcoming trip for adults - 25 mg, if necessary, the dose is repeated after 6 hours.

Children are prescribed half the adult dose.

The maximum daily dose should not exceed 225 mg.

With high sensitivity to the drug, treatment begins with 1/2 dose, increasing it gradually.

The course of treatment is from several weeks to several months.

Active ingredient: cinnarizine - 25 mg

Excipients : aerosil, calcium stearate, potato starch, lactose, low molecular weight medical polyvinylpyrrolidone.

• pregnancy,

• lactation period,

• children under 12 years of age;

• hypersensitivity to the drug.

Carefully: Parkinson's disease.

Instructions

Tablets, white or white with a creamy shade, flat-cylindrical, beveled, 50 pieces.

Composition:

Active ingredient: cinnarizine - 25 mg

Excipients : aerosil, calcium stearate, potato starch, lactose, low molecular weight medical polyvinylpyrrolidone.

Clinical and pharmacological group: Calcium channel blocker with a predominant effect on the vessels of the brain

Pharmaco-therapeutic group: BMCC

pharmachologic effect

Cinnarizine is a selective blocker of 'slow' calcium channels, reduces the intake of calcium ions into cells and reduces their concentration in the plasmolemma depot, reduces the tone of smooth muscles of arterioles, enhances the vasodilating effect of carbon dioxide. Directly affecting the smooth muscles of the vessels, it reduces their response to biogenic vasoconstrictor substances (adrenaline and norepinephrine). Has a vasodilating effect (especially in relation to the vessels of the brain), without significantly affecting blood pressure. Shows moderate antihistamine activity, reduces the excitability of the vestibular apparatus, lowers the tone of the sympathetic nervous system. Effective in patients with latent cerebral circulation insufficiency,initial atherosclerosis of cerebral vessels and chronic diseases of cerebral vessels with post-stroke focal symptoms. In patients with impaired peripheral circulation, it improves the blood supply to organs and tissues (including the myocardium), enhances postischemic vasodilation. Increases the elasticity of erythrocyte membranes, their ability to deform, reduces blood viscosity. Increases muscle resistance to hypoxia.

Pharmacokinetics

Cmax in blood plasma is achieved after oral administration in 1-3 hours. The connection with plasma proteins is about 91%. Completely metabolized in the liver by dealkylation. T1 / 2 - 4 hours. It is excreted in the form of metabolites: 1/3 - by the kidneys, 2/3 - by the intestines.

Indications

• the period of convalescence after suffering ischemic and hemorrhagic stroke, traumatic brain injury;

• encephalopathy;

• labyrinth disorders (including for maintenance therapy for dizziness, tinnitus, nystagmus, nausea, vomiting of labyrinthine origin);

• migraine (prevention of attacks);

• Meniere's disease;

• seasickness and air sickness (prevention);

• violation of peripheral circulation (prevention and treatment) - obliterating endarteritis, thromboangiitis obliterans, Raynaud's disease, diabetic angiopathy, thrombophlebitis, trophic disorders, trophic and varicose ulcers, pregangrenous conditions, paresthesias, night cramps and coldness in the extremities.

Dosage regimen

Inside, after eating. In case of cerebral circulation disorders - 25-50 mg 3 times a day; for violations of peripheral circulation - 50-75 mg 3 times a day; with labyrinth disorders - 25 mg 3 times a day; for sea ??and air sickness, before the upcoming trip for adults - 25 mg, if necessary, the dose is repeated after 6 hours. Children are prescribed half the dose for adults. The maximum daily dose should not exceed 225 mg.

With high sensitivity to the drug, treatment begins with 1/2 dose, increasing it gradually. The course of treatment is from several weeks to several months.

Side effect

From the nervous system: drowsiness, increased fatigue, headache, extrapyramidal disorders (tremor of the limbs and increased muscle tone, hypokinesia), depression.

From the digestive system: dry mouth, epigastric pain, dyspepsia, cholestatic jaundice.

On the part of the skin: increased sweating, lichen planus (extremely rare).

Allergic reactions: skin rash.

Others: a decrease in blood pressure, an increase in body weight, the development of a lupus-like syndrome.

Contraindications for use

• pregnancy,

• lactation period,

• children under 12 years of age;

• hypersensitivity to the drug.

Carefully: Parkinson's disease.

Application during pregnancy and lactation

Contraindicated during pregnancy and lactation.

Application for violations of liver function

With prolonged use, it is recommended to conduct a control examination of liver function.

Application for impaired renal function

With prolonged use, it is recommended to conduct a control examination of renal function.

Application in children

Contraindicated in children under 12 years of age.

special instructions

At the beginning of treatment, you should refrain from taking ethanol.

Due to the presence of an antihistamine effect, cinnarizine can affect the study result during anti-doping control of athletes (false positive result), as well as neutralize positive reactions during skin diagnostic tests (treatment should be canceled 4 days before the study).

With long-term use, it is recommended to conduct a control examination of the function of the liver, kidneys, and the picture of peripheral blood.

Breastfeeding is not recommended for women taking cinnarizine. Patients with Parkinson's disease should be prescribed only in cases where the benefits of its appointment outweigh the possible risk of worsening the condition.

Influence on the ability to drive vehicles and control mechanisms.

During the period of treatment, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions.

Overdose

Symptoms: vomiting, drowsiness, tremors, excessive drop in blood pressure, coma. In case of an overdose, there is no specific antidote, it is necessary to wash the stomach and take activated charcoal.

Treatment: symptomatic.

Drug interactions

Pharmaceutical: No known chemical incompatibility.

Pharmacodynamic: Enhances the effect of alcohol, sedatives and antidepressants. When used simultaneously with nootropic, antihypertensive and vasodilating agents, it enhances their effect, and when used simultaneously with drugs prescribed for arterial hypotension, it reduces their effect.

Pharmacokinetic: no data available.

Storage conditions

List B. In a dry, dark place at a temperature of 18 ? to 20 ? C. Keep out of the reach of children.

Shelf life

Shelf life is 2 years.

Terms of sale

On prescription.